Gilead and Arcus Advance Cancer Treatment Study with AB308 and Zimberelimab

Gilead Sciences ((GILD)), Arcus Biosciences ((RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.

Gilead Sciences and Arcus Biosciences are collaborating on a Phase 1/1b clinical study titled ‘A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies.’ The study aims to assess the safety, tolerability, and clinical activity of AB308 combined with zimberelimab (AB122) in patients with advanced cancers, which could potentially lead to new treatment options for these conditions.

The study involves the administration of two drugs: AB308 and zimberelimab. Both are given intravenously in various dosing schedules to determine the optimal dosage and assess their combined effects on different types of cancer.

This interventional study is non-randomized and follows a sequential intervention model with no masking, focusing primarily on treatment. The study is designed to escalate and expand doses to evaluate the drugs’ effects on different cancer types.

The study began on March 19, 2021, and is currently active but not recruiting new participants. The last update was submitted on July 28, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.

The study’s progress could influence the stock performance of Gilead Sciences and Arcus Biosciences by potentially enhancing their oncology portfolios. Positive results may boost investor confidence, while the competitive landscape in cancer treatment remains a critical factor.

The study is ongoing, and further details are available on the ClinicalTrials portal.